Sarepta Therapeutics マネジメント
マネジメント 基準チェック /44
Sarepta Therapeuticsの CEO はDoug Ingramで、 Jun2017年に任命され、 の在任期間は 7.42年です。 の年間総報酬は$ 1.66Mで、 48.1%給与と51.9%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.41%を直接所有しており、その価値は$ 43.13M 。経営陣と取締役会の平均在任期間はそれぞれ3.9年と8.5年です。
主要情報
Doug Ingram
最高経営責任者
US$1.7m
報酬総額
| CEO給与比率 | 48.1% |
| CEO在任期間 | 7.4yrs |
| CEOの所有権 | 0.4% |
| 経営陣の平均在職期間 | 3.9yrs |
| 取締役会の平均在任期間 | 8.5yrs |
経営陣の近況
Recent updates
Sarepta Therapeutics (NASDAQ:SRPT) Is Posting Healthy Earnings, But It Is Not All Good News
Nov 13
Is Sarepta Therapeutics (NASDAQ:SRPT) A Risky Investment?
Oct 20The Play On Sarepta Therapeutics
Sep 26Sarepta Therapeutics Muscles Up In DMD Race
Sep 19Sarepta Therapeutics' Pullback After Recent FDA Approval A Buying Opportunity
Jul 24Revenues Not Telling The Story For Sarepta Therapeutics, Inc. (NASDAQ:SRPT) After Shares Rise 28%
Jul 05Sarepta Therapeutics: Navigating Elevidys Upside Potential
Jun 17Sarepta Therapeutics' (NASDAQ:SRPT) Earnings Aren't As Good As They Appear
May 08Results: Sarepta Therapeutics, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
May 05Is Sarepta Therapeutics (NASDAQ:SRPT) Using Debt In A Risky Way?
Apr 15Sarepta Therapeutics: Growth Trajectory Alters Trading Strategy
Apr 11Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Mar 02Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Fly 29% But Investors Aren't Buying For Growth
Feb 06Sarepta Therapeutics: Navigating Elevidys Towards FDA Approval
Jan 22Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Could Be 50% Below Their Intrinsic Value Estimate
Jan 10There's No Escaping Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Muted Revenues
Dec 20Does Sarepta Therapeutics (NASDAQ:SRPT) Have A Healthy Balance Sheet?
Nov 29Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?
Aug 08Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?
Apr 30Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?
Jan 17Sarepta Therapeutics seeks FDA accelerated approval for muscle wasting therapy SRP-9001
Sep 29Sarepta Therapeutics announces offering of $1B of convertible senior notes due 2027
Sep 12Sarepta says FDA lifted clinical hold on Duchenne candidate
Sep 06Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?
Aug 22Sarepta inks licensing deal with Broad Institute for certain adeno-associated viruses
Aug 08Sarepta stock soars 19% on plans for US filing for gene therapy for neuromuscular disorder
Jul 29CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$122m |
| Jun 30 2024 | n/a | n/a | US$47m |
| Mar 31 2024 | n/a | n/a | US$17m |
| Dec 31 2023 | US$2m | US$800k | -US$536m |
| Sep 30 2023 | n/a | n/a | -US$691m |
| Jun 30 2023 | n/a | n/a | -US$908m |
| Mar 31 2023 | n/a | n/a | -US$1b |
| Dec 31 2022 | US$125m | US$740k | -US$703m |
| Sep 30 2022 | n/a | n/a | -US$716m |
| Jun 30 2022 | n/a | n/a | -US$507m |
| Mar 31 2022 | n/a | n/a | -US$357m |
| Dec 31 2021 | US$2m | US$730k | -US$419m |
| Sep 30 2021 | n/a | n/a | -US$486m |
| Jun 30 2021 | n/a | n/a | -US$634m |
| Mar 31 2021 | n/a | n/a | -US$704m |
| Dec 31 2020 | US$1m | US$669k | -US$554m |
| Sep 30 2020 | n/a | n/a | -US$601m |
| Jun 30 2020 | n/a | n/a | -US$530m |
| Mar 31 2020 | n/a | n/a | -US$656m |
| Dec 31 2019 | US$1m | US$650k | -US$715m |
| Sep 30 2019 | n/a | n/a | -US$620m |
| Jun 30 2019 | n/a | n/a | -US$570m |
| Mar 31 2019 | n/a | n/a | -US$403m |
| Dec 31 2018 | US$1m | US$650k | -US$362m |
| Sep 30 2018 | n/a | n/a | -US$245m |
| Jun 30 2018 | n/a | n/a | -US$216m |
| Mar 31 2018 | n/a | n/a | -US$170m |
| Dec 31 2017 | US$57m | US$338k | -US$51m |
報酬と市場: Dougの 総報酬 ($USD 1.66M ) は、 US市場 ($USD 12.67M ) の同様の規模の企業の平均を下回っています。
報酬と収益: Dougの報酬は、過去 1 年間の会社の業績と一致しています。
CEO（最高経営責任者
Doug Ingram (61 yo)
7.4yrs
在職期間
US$1,661,338
報酬
Mr. Douglas S. Ingram, also known as Doug, J.D., Esq., has been Chief Executive Officer and President of Sarepta Therapeutics, Inc. since June 26, 2017. Mr. Ingram serves as an Independent Director of Rela...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| President | 7.4yrs | US$1.66m | 0.41% $ 43.1m | |
| Executive VP & CFO | 3.9yrs | US$3.71m | 0.036% $ 3.8m | |
| Executive VP & Chief Technical Operations Officer | 1.9yrs | US$3.52m | 0.018% $ 1.9m | |
| Executive VP | 3.9yrs | US$3.72m | 0.076% $ 8.0m | |
| Executive VP | 3.9yrs | US$3.58m | 0.018% $ 1.9m | |
| Executive Director of Investor Relations and Corporate Communications | no data | データなし | データなし | |
| Executive VP & Chief People Officer | 3.1yrs | データなし | データなし | |
| Executive VP and Chief of Global Policy & Advocacy Officer | 5.2yrs | データなし | データなし | |
| Executive VP & Chief Customer Officer | 3.9yrs | データなし | 0.023% $ 2.4m | |
| Senior VP | 1.8yrs | データなし | データなし | |
| Controller & VP | 7.7yrs | US$911.89k | データなし | |
| Senior Manager of Investor Relations | no data | データなし | データなし |
3.9yrs
平均在職期間
50yo
平均年齢
経験豊富な経営陣: SRPTの経営陣は 経験豊富 であると考えられます ( 3.9年の平均在職年数)。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| President | 7.4yrs | US$1.66m | 0.41% $ 43.1m | |
| Independent Chairwoman | 15.7yrs | US$594.99k | 0.21% $ 22.0m | |
| Chairman of Corporate Strategy Board & Independent Non-Employee Director | 14.4yrs | US$546.99k | 0.022% $ 2.3m | |
| Independent Director | 9.4yrs | US$563.65k | 3.33% $ 351.4m | |
| Member of Strategic & Scientific Advisory Board | 9.3yrs | データなし | データなし | |
| Member of Scientific Advisory Board | 5yrs | データなし | データなし | |
| Member of Strategic & Scientific Advisory Board | 9.3yrs | データなし | データなし | |
| Independent Non-Employee Director | 9.4yrs | US$553.34k | 0.017% $ 1.8m | |
| Member of Strategic & Scientific Advisory Board | 7.7yrs | データなし | データなし | |
| Member of Scientific Advisory Board | 4.9yrs | データなし | データなし | |
| Member of Strategic & Scientific Advisory Board | 7.7yrs | データなし | データなし | |
| Member of Scientific Advisory Board | 5yrs | データなし | データなし |
8.5yrs
平均在職期間
71yo
平均年齢
経験豊富なボード: SRPTの 取締役会 は 経験豊富 であると考えられます ( 8.5年の平均在任期間)。